Triantafillos Liloglou received his B.S. degree (honors) in biology from the Aristotelian University of Thessaloniki in 1988 and his Ph.D. degree in molecular oncology from the Medical School of the University of Crete. Ever since, he has been working in the molecular pathogenesis of respiratory cancers. His early postdoctoral years focused on the genomic instability and involvement of p53 inactivation in tumor development and progression. In 1998, he joined the Liverpool Lung Project, which is the largest European population study for lung cancer. In there, he has been leading the Biomarkers group, aiming to develop assays that utilize cancer-specific molecular alterations and can assist in the clinical management of lung cancer: early detection, prediction of relapse, and therapeutic stratification. In the last decade, he particularly focused his research on epigenetics and DNA methylation. He was among the pioneers in using pyrosequencing for DNA methylation detection and has currently developed a novel method in collaboration with an industrial partner. His group is studying the epigenetic deregulation in lung cancer and develops biomarkers for early lung cancer detection utilizing samples such as sputum, plasma, oral scrapes, and bronchial washings. Liloglou is collaborating with multiple academic and industrial partners in various aspects of respiratory cancer biology and biomarker development. Currently undergoing retrospective validation of epigenetic markers, the Liverpool Lung project aims to undertake very soon prospective biomarker trials at both hospital and primary care levels.
Biography Updated on 16 June 2010